false
0001129928
0001129928
2026-01-14
2026-01-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 14, 2026
Oncolytics Biotech, Inc.
(Exact name of registrant as specified in its charter)
| Alberta, Canada |
001-38512 |
26-3847449 |
(State or other jurisdiction of
incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
4350 Executive Drive, Suite 325
San Diego, CA 92121 |
92121 |
| (Address of principal executive offices) |
(Zip Code) |
| |
|
| (403) 670-7377 |
| (Registrant's telephone number, including area code) |
| |
| N/A |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| |
|
|
|
|
| Common shares, no par value per share |
|
ONCY |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act
(§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events.
On January 14, 2026,
Oncolytics Biotech, Inc. (the “Company”) issued a press release announcing the appointment of John McAdory as Executive
Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. A copy of the press release is attached
hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.
In addition to any of the
Company’s filings with the U.S. Securities and Exchange Commission that automatically incorporate all filings made by the Company
pursuant to Sections 13(a), 13(c), 14, and 15(d) of the U.S. Securities and Exchange Act of 1934, as amended, this Current Report
on Form 8-K, including Exhibit 99.1 attached hereto, is hereby incorporated by reference as an exhibit to the Company’s Registration
Statement on Form F-3 (File No. 333-289819).
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
Description |
| |
|
| 99.1 |
Press Release issued by Oncolytics Biotech, Inc., dated as of January 14, 2026. |
| |
|
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: January 14, 2026
| |
ONCOLYTICS BIOTECH, INC. |
| |
|
|
| |
By: |
/s/ Kirk Look |
| |
Name: |
Kirk Look |
| |
Title: |
Chief Financial Officer |
